PetVivo Holdings Announces Executive and Board Changes
Ticker: PETVW · Form: 8-K · Filed: Apr 19, 2024 · CIK: 1512922
| Field | Detail |
|---|---|
| Company | Petvivo Holdings, Inc. (PETVW) |
| Form Type | 8-K |
| Filed Date | Apr 19, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $0.60, $90,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, executive-appointment
Related Tickers: PETV
TL;DR
PetVivo brings in new CMO & CSO, adds directors to the board.
AI Summary
On April 15, 2024, PetVivo Holdings, Inc. announced changes in its executive team and board of directors. The company appointed Dr. Brent R. Burns as Chief Medical Officer and Dr. Robert J. Valeri as Chief Scientific Officer. Additionally, Dr. Burns and Mr. David L. Johnson were elected to the Board of Directors.
Why It Matters
These appointments bring new leadership in medical and scientific roles, potentially impacting the company's product development and strategic direction.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and operational execution.
Key Players & Entities
- PetVivo Holdings, Inc. (company) — Registrant
- Dr. Brent R. Burns (person) — Appointed Chief Medical Officer and elected to Board of Directors
- Dr. Robert J. Valeri (person) — Appointed Chief Scientific Officer
- Mr. David L. Johnson (person) — Elected to Board of Directors
FAQ
What are the specific responsibilities of the newly appointed Chief Medical Officer and Chief Scientific Officer?
The filing states their appointments but does not detail their specific responsibilities beyond their titles.
What is the background of Dr. Brent R. Burns and Dr. Robert J. Valeri?
The filing does not provide biographical details or specific backgrounds for the newly appointed officers.
What is the reason for the changes in the Board of Directors?
The filing indicates elections to the Board of Directors but does not specify the reasons for these changes.
Are there any new compensatory arrangements for the newly appointed officers or directors?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item, but the details of these arrangements are not provided in the provided text.
When were these appointments and elections effective?
The earliest event reported is April 15, 2024, indicating the effective date for these changes.
Filing Stats: 458 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2024-04-19 16:49:05
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 PETV The Nasdaq Stock Market LLC
- $0.60 — he Company's common stock at a price of $0.60 per share and having an aggregate value
- $90,000 — share and having an aggregate value of $90,000. Each RSU represents an unfunded, unsec
Filing Documents
- form8-k.htm (8-K) — 36KB
- 0001493152-24-015357.txt ( ) — 247KB
- petv-20240415.xsd (EX-101.SCH) — 4KB
- petv-20240415_def.xml (EX-101.DEF) — 26KB
- petv-20240415_lab.xml (EX-101.LAB) — 36KB
- petv-20240415_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PETVIVO HOLDINGS, INC. Date: April 19, 2024 By: /s/ John Lai Name: John Lai Title: Chief Executive Officer 3